TP53 and neoplasm: Patients with basal/squamous MIBC often show TP53 and RB1 mutations, which are typically inactivating; these mutations contribute to genomic instability and enhance chemosensitivity to neoadjuvant chemotherapy by reducing the tumor’s ability to repair DNA damage effectively (10).